Download PDF
Semin Thromb Hemost 2002; 28(5): 447-454
DOI: 10.1055/s-2002-35285
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Anticoagulation with Recombinant Hirudin and Danaparoid Sodium in Pediatric Patients

Thomas Severin, Barbara Zieger, Anton H. Sutor
  • Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg, Germany
Further Information

Publication History

Publication Date:
06 November 2002 (online)

    Permissions and Reprints

ABSTRACT

Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have been reported in a study on newborns and in a few reports on children and adolescents. However, thrombotic complications can be as severe in children as they are in adults. In the case of HIT II, the withdrawal of heparin is required and alternative anticoagulation should be started. In contrast to numerous investigations in adult patients, including prospective studies, experience with alternative anticoagulants in pediatric patients is limited. The available data were analyzed according to HIT II complications, alternative anticoagulation, and clinical outcome. In conclusion, HIT II represents a potentially dangerous complication of heparin therapy in pediatric patients also. Alternative anticoagulation applied in pediatric patients mainly included danaparoid sodium and recombinant hirudin. In most patients treated with these anticoagulants, effective anticoagulation and clinical improvement were observed. Because of limited experience, more data are required for optimal management of HIT II in young patients.

KEYWORDS

Heparin-induced thrombocytopenia - HIT - anticoagulation - children - thrombosis

REFERENCES

  • 1 Andrew M, Michelson A D, Bovill E. Guidelines for antithrombotic therapy in pediatric patients.  J Pediatr . 1998;  132 575-588
    PubMedGoogle Scholar
  • 2 Sutor A H. Thrombosis in Childhood.  New York: Schattauer 1997
    Google Scholar
  • 3 Streif W, Mitchell L G, Andrew M. Antithrombotic therapy in children.  Curr Opin Pediatr . 1999;  11 56-64
    CrossrefPubMedGoogle Scholar
  • 4 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest . 2001;  119(Suppl 1) 344S-370S
    CrossrefPubMedGoogle Scholar
  • 5 Sutor A H, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients.  Semin Thromb Hemost . 1997;  23 303-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Fareed J, Hoppensteadt D A, Bick R L. An update on heparins at the beginning of the new millennium.  Semin Thromb Hemost . 2000;  26(Suppl 1) 5-21
    PubMedGoogle Scholar
  • 7 Massicotte M P. Low-molecular-weight heparin therapy in children.  J Pediatr Hematol Oncol . 2001;  23 189-194
    CrossrefPubMedGoogle Scholar
  • 8 Greinacher A. Heparin-induced thrombocytopenia-pathogenesis and treatment [in German].  Hämostaseologie . 1999;  19 1-12
    PubMedGoogle Scholar
  • 9 Greinacher A. Treatment of heparin-induced thrombocytopenia.  Thromb Haemost . 1999;  82 457-467
    PubMedGoogle Scholar
  • 10 Visentin G P. Heparin-induced thrombocytopenia: molecular pathogenesis.  Thromb Haemost . 1999;  82 448-456
    PubMedGoogle Scholar
  • 11 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost . 1998;  79 1-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Fabris F, Ahmad S, Cella G. Pathophysiology of heparin-induced thrombocytopenia.  Arch Pathol Lab Med . 2000;  124 1657-1666
    PubMedGoogle Scholar
  • 13 Warkentin T E, Soutar R L, Panju A, Ginsberg J S. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia (Abst).  Blood . 1992;  80 160a
    PubMedGoogle Scholar
  • 14 Ali O. Images in heparin-induced thrombocytopenia.  J Thromb Thrombolysis . 2000;  10 S27-S33
    CrossrefPubMedGoogle Scholar
  • 15 Warkentin T E. Heparin-induced skin lesions.  Br J Haematol . 1996;  92 494-497
    CrossrefPubMedGoogle Scholar
  • 16 Hartman A R, Hood R M, Anagnostopoulus C E. Phenomenon of heparin-induced thrombocytopenia associated with skin necrosis.  J Vasc Surg . 1988;  7 781-784
    PubMedGoogle Scholar
  • 17 Warkentin T E, Hirte H W, Anderson D R. Transient global amnesia associated with acute heparin-induced thrombocytopenia.  Am J Med . 1994;  97 489-491
    CrossrefPubMedGoogle Scholar
  • 18 Kadidal V V, Mayo D J, Horne M K. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases.  J Intern Med . 1999;  246 325-329
    CrossrefPubMedGoogle Scholar
  • 19 Walenga J M, Lewis B E, Bakhos M. Anticoagulant management of patients with heparin-induced thrombocytopenia.  Turk J Haematol . 2000;  17(Suppl) 68-77
    PubMedGoogle Scholar
  • 20 Magnani H N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran.  Thromb Haemost . 1993;  70 554-561
    PubMedGoogle Scholar
  • 21 Chong B H, Magnani H N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia New York: Dekker 2001: 323-347
    Google Scholar
  • 22 Greinacher A. Recombinant hirudin for further anticoagulation in heparin-induced thrombocytopenia [in German].  Hämostaseologie . 1999;  19 19-29
    PubMedGoogle Scholar
  • 23 Greinacher A, Völpel H, Janssens U. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia.  Circulation . 1999;  99 73-80
    CrossrefPubMedGoogle Scholar
  • 24 Greinacher A, Janssens U, Berg G, for the Heparin-Associated Thrombocytopenia (HAT) Study investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia.  Circulation . 1999;  100 587-593
    CrossrefPubMedGoogle Scholar
  • 25 Spadone D, Clark F, James E. Heparin-induced thrombocytopenia in the newborn.  J Vasc Surg . 1992;  15 306-311
    PubMedGoogle Scholar
  • 26 Laster J, Cikrit D, Walker N. The heparin-induced thrombocytopenia syndrome: an update.  Surgery . 1987;  102 763-770
    PubMedGoogle Scholar
  • 27 Boon D MS, Michiels J J, Stibbe J, van Vliet H D M H, Kappers-Klunne M C. Heparin-induced thrombocytopenia and antithrombotic therapy.  Lancet . 1994;  344 1296
    PubMedGoogle Scholar
  • 28 Butler T J, Sodoma L J, Doski J J. Heparin-associated thrombocytopenia and thrombosis as the cause of a fatal thrombus on extracorporeal membrane oxygenation.  J Pediatr Surg . 1997;  32 768-771
    CrossrefPubMedGoogle Scholar
  • 29 Ranze O, Ranze P, Magnani H N, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients-a review of the literature and a new case treated with danaparoid sodium.  Eur J Pediatr . 1999;  158(Suppl 3) 130-133
    PubMedGoogle Scholar
  • 30 Murdoch I A, Beattie R M, Silver D M. Heparin-induced thrombocytopenia in children.  Acta Paediatr . 1993;  82 495-497
    PubMedGoogle Scholar
  • 31 Oriot D, Wolf M, Wood C. Severe thrombocytopenia induced by heparin in an infant with acute myocarditis.  Arch Fr Pediatr . 1990;  47 357-359
    PubMedGoogle Scholar
  • 32 Saxon B R, Black M D, Edgell D, Noel D, Leaker M T. Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran).  Ann Thorac Surg . 1999;  68 1076-1078
    CrossrefPubMedGoogle Scholar
  • 33 Zöhrer B, Zenz W, Rettenbacher A. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.  Acta Paediatr . 2001;  90 765-771
    PubMedGoogle Scholar
  • 34 Neuhaus T J, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.  Pediatr Nephrol . 2000;  14 713-716
    PubMedGoogle Scholar
  • 35 Schiffmann H, Unterhalt M, Harms K. Successful treatment of heparin-induced thrombocytopenia type II in childhood with recombinant hirudin [in German].  Monatsschr Kinderheilkd . 1997;  145 606-612
    CrossrefPubMedGoogle Scholar
  • 36 Potter C, Gill J C, Scott J P, McFarland J G. Heparin-induced thrombocytopenia in a child.  J Pediatr . 1992;  121 135-138
    PubMedGoogle Scholar
  • 37 Bocquet R, Blanot S, Dautzenberg M D. Antiphospholipid antibody syndrome in pediatric neurosurgery: a hemostasis problem.  Ann Fr Anesth Reanim . 1999;  18 991-995
    CrossrefPubMedGoogle Scholar
  • 38 Wilhelm M J, Schmid C, Kececioglu D. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172.  Ann Thorac Surg . 1996;  61 920-924
    CrossrefPubMedGoogle Scholar
  • 39 Severin T, Ensenauer R, Wiedensohler A. HIT type II without thrombocytopenia in a 15-year-old boy with protein S deficiency and recurrent deep vein thrombosis. Proceedings of the 30th Hemophilia Symposium; 1999; Hamburg, Germany. New York: Springer-Verlag 2000: 114-116
    Google Scholar
  • 40 Klement D, Rammos S, von Kries R. Heparin as a cause of thrombus progression.  Eur J Pediatr . 1996;  155 11-14
    PubMedGoogle Scholar
  • 41 Sauer M, Gruhn B, Fuchs D, Altermann W, Zintl F. Heparin-induced thrombocytopenia type II during high-dose-chemotherapy with stem cell rescue [in German].  Klein Pädiatr . 1998;  210 102-105
    PubMedGoogle Scholar
  • 42 Severin T, Sutor A H. Heparin-induced thrombocytopenia in pediatrics.  Semin Thromb Hemost . 2001;  27 293-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Weigel B, Lasky A, Krishnamurti L. Danaparoid (Orgaran) anticoagulation of pediatric patients with heparin-induced thrombocytopenia (HIT) (Abst).  J Pediatr Hematol Oncol . 1999;  21 327
    PubMedGoogle Scholar
  • 44 Girisch M, Buheitel G, Ries M, Klinge J. Safe and effective use of danaparoid during cardiac catheterization in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia.  Ann Hematol . 2001;  80(Suppl 1) A20
    PubMedGoogle Scholar
  • 45 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia New York: Dekker 2001: 291-322
    Google Scholar
  • 46 Product Information: Orgaran Thiemann GmbH, Waltrop, Germany . 
    Google Scholar
  • 47 Roth B, Johnen M, Busch P. Use of a new heparinoid for anticoagulation during hemodialysis in a child with intracranial hemorrhage [in German].  Nieren-u. Hochdruckkrankheiten . 1985;  14 62-64
    PubMedGoogle Scholar
  • 48 Lubenow N, Greinacher A. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.  J Thromb Thrombolysis . 2000;  10 47-57
    CrossrefPubMedGoogle Scholar
  • 49 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice.  Circulation . 2001;  103 1479-1484
    PubMedGoogle Scholar
  • 50 Product Information: Refludan Aventis, Frankfurt, Germany . 
    Google Scholar
  • 51 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
      >